February 21, 2024
1 min watch
Save
VIDEO: Psoriasis patients can switch medications, still receive effective treatment
You've successfully added to your alerts. You will receive an email when new content is published.
Click Here to Manage Email Alerts
Click Here to Manage Email Alerts
We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.
In this Healio exclusive video, Raj Chovatiya, MD, PhD, discussed research into the interleukin-17 inhibitor ixekizumab from the Maui Derm 2024 meeting.
Chovatiya, assistant professor of dermatology at Northwestern University Feinberg School of Medicine, discussed a 6-month, real-world study of patients who switched from an IL-23 inhibitor to ixekizumab (Taltz, Eli Lilly & Co.).
“(The data suggests) that whatever order you seem to choose with your medications, as long as you’re sort of switching between mechanisms of action, you can actually help patients achieve very high endpoints for efficacy in a very safe way,” Chovatiya said.
Published by:
Sources/Disclosures
Collapse
Source:
Healio Interview
Disclosures:
Chovatiya reports being an advisor, consultant, speaker and/or investigator for AbbVie, Apogee Therapeutics, Arcutis, Argenx, ASLAN Pharmaceuticals, Beiersdorf, Boehringer Ingelheim, Bristol Myers Squibb, Cara Therapeutics, Dermavant, Eli Lilly and Company, FIDE, Galderma, Genentech, GSK, Incyte, Janssen, LEO Pharma, L’Oréal, Nektar Therapeutics, Opsidio, Pfizer Inc., Regeneron, RAPT, Sanofi and UCB.
Read more about
You've successfully added to your alerts. You will receive an email when new content is published.
Click Here to Manage Email Alerts
Click Here to Manage Email Alerts
We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.